Use and Impact of the 21-Gene Recurrence Score in Relation to the Clinical Risk of Developing Metastases in Early Breast Cancer Patients in the Netherlands-Reference-Cited by-同舟云学术

Use and Impact of the 21-Gene Recurrence Score in Relation to the Clinical Risk of Developing Metastases in Early Breast Cancer Patients in the Netherlands

Published:2018 Issue:1-2 Volume:21 Page:85-92
ISSN:1662-4246
Container-title:Public Health Genomics
language:en
Short-container-title:Public Health Genomics

Author:

Schreuder Kay,Kuijer Anne,Bentum Sanne,van Dalen Thijs,Siesling Sabine

Publisher

S. Karger AG

Subject

Genetics (clinical),Public Health, Environmental and Occupational Health

Reference16 articles.

1. Collaborative EB; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 May;365(9472):1687–717.

2. Beisecker A, Cook MR, Ashworth J, Hayes J, Brecheisen M, Helmig L, et al. Side effects of adjuvant chemotherapy: perceptions of node-negative breast cancer patients. Psychooncology. 1997 Jun;6(2):85–93.

3. Kuijer A, van Bommel AC, Drukker CA, van der Heiden-van der Loo M, Smorenburg CH, Westenend PJ, et al. Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study. Genet Med. 2016 Jul;18(7):720–6.

4. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015 Nov;373(21):2005–14.

5. Sánchez-Forgach ER, Carpinteyro-Espín U, Alemán-Áviles JA, Sánchez-Basurto C. Validation and clinical application of MammaPrint® in patients with breast cancer. Cir Cir. 2017 Jul–Aug;85(4):320–4. Spanish.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing Genetic Risk and Clinical Risk Classification in Luminal-like Breast Cancer Patients Using a 23-Gene Classifier;Cancers;2022-12-19

2. Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients;European Journal of Surgical Oncology;2021-08

3. Personalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence – a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2020-06-05

4. Comparison of 21-gene assay and St.Gallen International Expert Consensus in the treatment decision for patients with early invasive breast cancers;Cancer Biology & Therapy;2019-10-30